The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://anniebyld055130.wikisona.com/2022010/retatrutide_vs_tirzepatide_a_comparative_analysis